ARTICLE | Product Development
Cytokinetics plans for commercial transition as CV programs progress
Positive Phase II readout for CK-274 puts the HCM candidate on track for Phase III testing this year
July 19, 2021 11:31 AM UTC
With its hypertrophic cardiomyopathy program slated to enter Phase III testing by year-end and a planned NDA submission for its heart failure candidate, Cytokinetics is actively building out its cardiovascular commercial workforce.
Top-line data from the first two cohorts of the Phase II REDWOOD-HCM trial showed treatment with CK-274 for 10 weeks led to significant dose-dependent reductions in average resting left ventricular outflow tract (LVOT) pressure gradient and average post-Valsalva LVOT pressure gradient (p<0.0001) from baseline vs. placebo in patients with obstructive HCM. ...